Reported 3 months ago
Shares of Novo Nordisk and Eli Lilly dipped as Roche's weight-loss drug, CT-996, demonstrated positive early-stage data with a placebo-adjusted mean weight loss of 6.1% in obesity patients without diabetes. This non-injectable pill poses potential competition to Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Roche acquired CT-996 from Carmot Therapeutics in a move to expand its weight-loss drug portfolio, but it may take several years before the drug becomes available in the market. Roche's stock surged more than 6%, while Eli Lilly and Novo Nordisk stocks dropped by 3% and 4%, respectively.
Source: YAHOO